Clarification; each of the passages should have been bulleted to indicate they came from different sections of the paper. Also, the first paragraph/bullet was pasted because I thought interesting that NCCN now recommends standard molecular profiling to detect mutations for NSCLC. So that becomes part of Std of Care making it easier to determine if a patient should get what drug. That was one of the concerns w LOXO's Vitrakvi for patients with advanced solid tumors containing what’s called an NTRK gene fusion. Those tests weren't standard when Bayer bought rights to the drug. They might be now.
News 
Market Data 
Discover 
